PDF(Pubmed)
Abstract：
UNASSIGNED: Osimertinib is the treatment of choice for epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC). Because of its high price, many low-income countries, such as Syria, cannot provide osimertinib, which makes it difficult to choose the appropriate treatment for these patients. This study aimed to review articles that assessed tyrosine kinase inhibitors (TKIs) for advanced NSCLC and developed an appropriate treatment plan for Syrian patients.
UNASSIGNED: An electronic literature search was conducted of published phase II and III studies that assessed the efficacy of EGFR-TKIs for advanced NSCLC between January 2003 and May 2022.
UNASSIGNED: Seventeen articles were reviewed. The results were similar when erlotinib or icotinib was compared with gefitinib. Progression-free survival and overall survival for afatinib and dacomitinib were longer than for gefitinib, with small significant differences. Osimertinib was the only TKI that showed efficacy against the T790M mutation, which showed an improvement over the first- and second-generation TKIs. Osimertinib as a first-line therapy is not cost-effective compared with first- and second-generation TKIs.
UNASSIGNED: Osimertinib is the preferred first-line treatment in patients with advanced EGFR-mutated NSCLC. First- and second-generation TKIs are still considered good options, especially in low-income countries that cannot cover the costs of osimertinib.
UNASSIGNED: An electronic literature search was conducted of published phase II and III studies that assessed the efficacy of EGFR-TKIs for advanced NSCLC between January 2003 and May 2022.
UNASSIGNED: Seventeen articles were reviewed. The results were similar when erlotinib or icotinib was compared with gefitinib. Progression-free survival and overall survival for afatinib and dacomitinib were longer than for gefitinib, with small significant differences. Osimertinib was the only TKI that showed efficacy against the T790M mutation, which showed an improvement over the first- and second-generation TKIs. Osimertinib as a first-line therapy is not cost-effective compared with first- and second-generation TKIs.
UNASSIGNED: Osimertinib is the preferred first-line treatment in patients with advanced EGFR-mutated NSCLC. First- and second-generation TKIs are still considered good options, especially in low-income countries that cannot cover the costs of osimertinib.
摘要：
■奥希替尼是表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌（NSCLC）的首选治疗药物。因为它的高价格，许多低收入国家，比如叙利亚,不能提供奥希替尼，这使得很难为这些患者选择合适的治疗方法。这项研究旨在回顾评估酪氨酸激酶抑制剂（TKIs）治疗晚期NSCLC的文章，并为叙利亚患者制定适当的治疗方案。
■对2003年1月至2022年5月之间已发表的II期和III期研究进行了电子文献检索，这些研究评估了EGFR-TKIs对晚期NSCLC的疗效。
■共审查了17篇文章。当厄洛替尼或埃克替尼与吉非替尼相比较时,结果相似。阿法替尼和达科替尼的无进展生存期和总生存期长于吉非替尼，具有微小的显著差异。奥希替尼是唯一对T790M突变有效的TKI，与第一代和第二代TKIs相比有了改进。与第一代和第二代TKIs相比，奥希替尼作为一线疗法并不具有成本效益。
■奥希替尼是晚期EGFR突变非小细胞肺癌患者首选的一线治疗药物。第一代和第二代TKIs仍然被认为是不错的选择，尤其是在无法支付奥希替尼费用的低收入国家.
■对2003年1月至2022年5月之间已发表的II期和III期研究进行了电子文献检索，这些研究评估了EGFR-TKIs对晚期NSCLC的疗效。
■共审查了17篇文章。当厄洛替尼或埃克替尼与吉非替尼相比较时,结果相似。阿法替尼和达科替尼的无进展生存期和总生存期长于吉非替尼，具有微小的显著差异。奥希替尼是唯一对T790M突变有效的TKI，与第一代和第二代TKIs相比有了改进。与第一代和第二代TKIs相比，奥希替尼作为一线疗法并不具有成本效益。
■奥希替尼是晚期EGFR突变非小细胞肺癌患者首选的一线治疗药物。第一代和第二代TKIs仍然被认为是不错的选择，尤其是在无法支付奥希替尼费用的低收入国家.
